equillium
announces
successful
completion
fda
meeting
enabling
advancement
itolizumab
potential
registration
study
treatment
hospitalized
patients
equillium
anticipates
filing
ind
itolizumab
initiating
global
phase
clinical
study
la
jolla
globe
newswire
equillium
nasdaq
eq
biotechnology
company
developing
itolizumab
treat
severe
autoimmune
inflammatory
disorders
today
announced
completed
new
drug
ind
meeting
food
drug
administration
fda
coronavirus
treatment
acceleration
program
ctap
fda
provided
positive
feedback
supporting
equillium
clinical
development
plans
evaluating
itolizumab
potential
treatment
hospitalized
patients
feedback
equillium
plans
finalizing
protocol
anticipates
submitting
ind
application
fda
october
preparation
initiating
global
phase
randomized
clinical
trial
fourth
quarter
year
time
equillium
anticipates
beginning
formal
applications
governmental
agencies
funding
support
clinical
study
importantly
fda
indicated
proposed
study
meets
primary
key
secondary
endpoints
may
sufficient
biologic
license
application
bla
submission
feedback
fda
significant
milestone
equillium
executing
clinical
development
program
itolizumab
treating
hospitalized
patients
suffering
consequences
result
said
bruce
steel
chief
executive
officer
equillium
believe
itolizumab
novel
mechanism
regulates
cytokine
cascade
data
prior
human
clinical
trials
including
recent
positive
interim
data
phase
clinical
study
acute
disease
phase
study
data
patients
reported
partner
biocon
limited
support
hypothesis
itolizumab
may
promise
addressing
complications
experienced
patients
guidance
fda
provides
us
regulatory
pathway
continue
working
expeditiously
file
ind
goal
initiating
study
meeting
provides
opportunity
open
communication
sponsor
fda
discuss
ind
development
plan
obtain
fda
guidance
clinical
trials
sponsor
drug
candidate
fda
created
ctap
special
emergency
program
possible
coronavirus
therapies
designed
use
every
available
method
move
new
treatments
patients
quickly
possible
evaluating
safety
effectiveness
equillium
equillium
biotechnology
company
leveraging
deep
understanding
immunobiology
develop
novel
products
treat
severe
autoimmune
inflammatory
disorders
high
unmet
medical
need
equillium
initial
product
candidate
itolizumab
monoclonal
antibody
selectively
targets
pathway
pathway
plays
central
role
modulating
activity
trafficking
cells
drive
number
diseases
equillium
acquired
rights
itolizumab
exclusive
partnership
biocon
limited
itolizumab
currently
marketed
biocon
india
trade
name
alzumab
treatment
chronic
plaque
psoriasis
july
received
emergency
use
approval
india
treat
cytokine
release
syndrome
crs
patients
moderate
severe
acute
respiratory
distress
syndrome
ards
equillium
believes
itolizumab
potential
disease
modifying
therapeutic
several
indications
developing
itolizumab
multiple
severe
disorders
acute
disease
uncontrolled
asthma
lupus
nephritis
planning
submit
investigational
new
drug
application
treatment
patients
information
visit
forward
looking
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
potential
benefit
treating
patients
itolizumab
equillium
business
strategy
equillium
plans
expected
timing
developing
itolizumab
including
ability
submit
ind
fda
initiate
clinical
trial
patients
potential
benefits
itolizumab
equillium
ability
submit
applications
receive
funding
support
clinical
trial
patients
whether
clinical
trial
sufficient
support
bla
application
equillium
cash
runway
impact
pandemic
risks
contribute
uncertain
nature
statements
include
uncertainties
related
equillium
capital
requirements
equillium
plans
product
development
including
initiation
restarting
completion
clinical
trials
including
clinical
trial
patients
uncertainties
related
actual
impacts
length
impacts
caused
pandemic
uncertainties
caused
recent
restarting
equip
equalise
clinical
trials
pause
whether
results
clinical
trials
validate
support
safety
efficacy
itolizumab
use
cash
ways
timing
expected
impact
market
volatility
cash
reserves
risks
uncertainties
described
fully
caption
risk
factors
elsewhere
equillium
filings
reports
united
states
securities
exchange
commission
statements
contained
press
release
speak
date
made
equillium
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
investor
contact
christine
zedelmayer
chief
operating
officer
ir
media
contact
cammy
duong
canale
communications
cammy
